Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 108 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $109,469 | -19.7% | 20,086 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $136,384 | +35.5% | 20,086 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $100,631 | +56.3% | 20,086 | +52.3% | 0.00% | 0.0% |
Q4 2022 | $64,372 | -78.4% | 13,191 | -36.2% | 0.00% | -66.7% |
Q3 2022 | $298,249 | -4.7% | 20,683 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $312,934 | +27.4% | 20,683 | 0.0% | 0.00% | +50.0% |
Q1 2022 | $245,714 | +13.0% | 20,683 | +54.2% | 0.00% | 0.0% |
Q4 2021 | $217,457 | -43.2% | 13,415 | 0.0% | 0.00% | -50.0% |
Q3 2021 | $382,864 | -15.6% | 13,415 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $453,427 | +11.8% | 13,415 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $405,670 | -38.9% | 13,415 | 0.0% | 0.00% | -42.9% |
Q4 2020 | $664,177 | +29.0% | 13,415 | 0.0% | 0.01% | +16.7% |
Q3 2020 | $515,002 | -11.1% | 13,415 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $579,528 | +120.5% | 13,415 | +33.2% | 0.01% | +75.0% |
Q1 2020 | $262,853 | -16.5% | 10,071 | 0.0% | 0.00% | +33.3% |
Q4 2019 | $314,719 | +19.9% | 10,071 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $262,450 | – | 10,071 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $932,939 | 3.08% |
Sofinnova Investments, Inc. | 2,194,278 | $10,708,077 | 0.64% |
Artal Group S.A. | 400,000 | $1,952 | 0.11% |
Polar Capital Holdings Plc | 1,991,929 | $9,720,614 | 0.08% |
ASHFORD CAPITAL MANAGEMENT INC | 98,870 | $482,486 | 0.08% |
Soleus Capital Management, L.P. | 87,182 | $425,448 | 0.06% |
GSA CAPITAL PARTNERS LLP | 99,160 | $484 | 0.06% |
Cormorant Asset Management, LP | 150,000 | $732 | 0.05% |
CORNERCAP INVESTMENT COUNSEL INC | 48,233 | $235,377 | 0.04% |
XTX Topco Ltd | 38,574 | $188,241 | 0.04% |